Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of HRTX, CLDR and EROS

EMWPF, HRTX

CEDARHURST, NY / ACCESSWIRE / June 28, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Heron Therapeutics, Inc. (NASDAQ: HRTX)

Investors Affected : October 31, 2018 - April 30, 2019

A class action has commenced on behalf of certain shareholders in Heron Therapeutics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls ("CMC") and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron's NDA for HTX-011; and (iii) as a result, Heron's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/heron-therapeutics-inc-loss-submission-form/?id=2159&from=1

Cloudera, Inc. (NYSE: CLDR)

Investors Affected : April 28, 2017 - June 5, 2019

A class action has commenced on behalf of certain shareholders in Cloudera, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Cloudera was finding it increasingly difficult to identify large enterprises interested in adopting the Company's Hadoop-based platform; (ii) Cloudera needed to expend an increasing amount of capital on sales and marketing activities to generate new revenues, even as new revenue opportunities were diminishing; and (iii) Cloudera had materially diminished sales opportunities and prospects and could not generate annual positive cash flows.

Shareholders may find more information at https://kclasslaw.com/securities/cloudera-inc-loss-submission-form/?id=2159&from=1

Eros International Plc (NYSE: EROS)

Investors Affected : July 28, 2017 - June 5, 2019

A class action has commenced on behalf of certain shareholders in Eros International Plc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Eros and its executives engaged in a scheme to use related-party
transactions to fabricate receivables that they reported in Eros's public financial disclosures; (2) because of this scheme, Eros's financial position was weaker than what the Company disclosed; (3) consequently, the Company's Indian subsidiary, Eros International Media Ltd ("EIML"), missed loan payments and had its credit
downgraded; and (4) due to the foregoing, Defendants' statements about Eros's receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/eros-international-plc-loss-submission-form/?id=2159&from=1

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.

CONTACT:

Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967

SOURCE: Kuznicki Law PLLC



View source version on accesswire.com:
https://www.accesswire.com/550363/FILING-DEADLINE-Kuznicki-Law-PLLC-Announces-Class-Actions-on-Behalf-of-Shareholders-of-HRTX-CLDR-and-EROS



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today